Gastrointestinal Stromal Tumor (GIST) in Childhood: Symptoms, Diagnosis and Treatment — Overview, Diagnosis & Treatment Options | MyMedicPlus

Gastrointestinal stromal tumors (GISTs) in childhood are rare mesenchymal neoplasms arising from the interstitial cells of Cajal (pacemaker cells of the GI tract). They account for fewer than 2% of all GISTs and represent the most common GI mesenchymal tumors in adults but are exceptionally rare in the pediatric population (annual incidence approximately 1 per 10 million children). Pediatric GISTs differ fundamentally from adult GISTs at the molecular level: whereas adult GISTs harbor activating mutations in KIT (80%) or PDGFRA (10%), pediatric GISTs are predominantly 'wild-type' — lacking these mutations — and instead exhibit deficiency of succinate dehydrogenase (SDH) complex subunits (SDHA, SDHB, SDHC, SDHD) in approximately 85% of cases. SDH-deficient GISTs predominantly affect girls, arise in the gastric antrum, are multifocal, and have indolent behavior despite nodal and hepatic metastases. They are associated with Carney triad (GIST, pulmonary chondroma, paraganglioma) and Carney-Stratakis syndrome (familial GIST and paraganglioma). Rare pediatric GISTs carry NF1 mutations or BRAF/KRAS alterations.

The molecular pathogenesis of pediatric GIST differs substantially from adult disease. SDH-deficient GISTs result from loss-of-function mutations or epigenetic silencing of SDH subunit genes, impairing mitochondrial function and activating hypoxia-inducible pathways. Unlike KIT/PDGFRA-mutant GISTs, where driver mutations are somatic, SDH subunit mutations may be germline (Carney-Stratakis syndrome) or somatic. Carney triad — the combination of GIST, pulmonary chondroma, and paraganglioma — occurs predominantly in young females (85%) and is caused by epigenetic silencing of SDHC without a germline mutation. Neurofibromatosis type 1 (NF1)-associated GISTs are another pediatric variant: KIT/PDGFRA-wild-type tumors occurring in the small intestine. Familial GIST syndromes (germline KIT or PDGFRA mutations) cause multicentric GISTs in adults and rarely in older adolescents. Radiation exposure and prior H. pylori infection are not established pediatric risk factors.

Pediatric GISTs most commonly arise in the stomach and present with gastrointestinal bleeding — either hematemesis, melena, or iron-deficiency anemia — as the dominant symptom. Chronic, recurrent upper GI bleeding in an adolescent female should raise suspicion for gastric GIST. Abdominal pain is present in approximately 40% of patients. A palpable abdominal mass is found in 20–30%. Intestinal obstruction, vomiting, and weight loss may occur with larger lesions. Unlike adult GISTs, pediatric tumors are often multifocal within the stomach. Nodal metastases to omental and perigastric nodes occur in 50% of SDH-deficient GISTs at diagnosis, and hepatic metastases develop in 30%, yet patients frequently maintain a prolonged clinical course and good functional status. Symptoms of paraganglioma (hypertension, palpitations, sweating) or pulmonary chondroma (incidental nodule on imaging) may co-exist in Carney triad.

Upper endoscopy identifies submucosal gastric masses; EUS confirms the submucosal origin, assesses size, echogenicity, and guides biopsy. CT chest/abdomen/pelvis delineates the primary tumor and identifies metastases. PET-CT with FDG is useful for KIT/PDGFRA-mutant tumors but may be negative in SDH-deficient GISTs due to lower metabolic activity. Biopsy is required for histological and molecular characterization: immunohistochemistry for CD117 (KIT), DOG1 (ANO1), CD34, and SDHB is essential. SDHB loss on IHC identifies SDH-deficient tumors (sensitivity ~85%). Molecular profiling (KIT/PDGFRA/SDHA/SDHB mutational analysis by next-generation sequencing) is mandatory to guide therapy selection, as treatment response differs by genotype. MRI of the abdomen is preferred for liver lesion characterization. Genetic counselling and germline testing for SDH subunit mutations should be offered to all pediatric GIST patients.

Surgical resection with negative margins is the primary curative treatment for localized GIST, aiming to avoid tumor rupture (which dramatically worsens prognosis). Wedge gastrectomy or partial gastrectomy preserving gastric volume is preferred in young patients. Imatinib (Gleevec, 400 mg/day) is the first-line targeted therapy for KIT exon 11- or exon 9-mutant GISTs — per NCCN guidelines, adjuvant imatinib is given for 3 years in high-risk resected adult GIST (with pediatric data extrapolated). However, SDH-deficient pediatric GISTs are imatinib-resistant; these patients have limited systemic options. Sunitinib has modest activity in SDH-deficient disease. Regorafenib is third-line therapy for KIT/PDGFRA-mutant GIST after imatinib and sunitinib failure per CORRECT trial. Avapritinib is approved for PDGFRA D842V-mutant GIST. COG ARST1321 trial explored novel agents in pediatric GIST. Surgery for metastatic disease (cytoreduction) can be beneficial in SDH-deficient GIST given the indolent course.

Prognosis for pediatric GIST depends primarily on molecular subtype, resectability, and extent of disease. SDH-deficient GIST — the dominant pediatric subtype — has an indolent clinical course despite frequent nodal and hepatic metastases at diagnosis: median overall survival exceeds 10–15 years even with metastatic disease, and patients can live decades with good quality of life. Localized GIST resected with negative margins carries a 5-year survival approaching 95% for SDH-deficient variants, as recurrence is slow. KIT/PDGFRA-mutant pediatric GIST (rare) follows adult prognosis models: risk stratification by tumor size, mitotic rate, and site guides adjuvant imatinib use. Key prognostic factors include completeness of resection (negative margins), tumor rupture (which significantly worsens prognosis), histological grade (mitotic index), and genotype — SDH-deficient tumors respond to surgery; KIT-mutant tumors respond to imatinib. Post-resection surveillance involves 3–6 monthly CT or MRI for 5 years, transitioning to annual imaging thereafter. SDH-deficient GIST patients require lifelong monitoring given the potential for late recurrence 10–20+ years after initial resection. Carney triad and Carney-Stratakis patients require surveillance not just for GIST but also for paraganglioma and pulmonary chondroma throughout their lifetime.

No strategies prevent sporadic pediatric GIST. Genetic counselling and germline SDH subunit mutation testing should be offered to all pediatric patients, as Carney-Stratakis syndrome is inherited in an autosomal dominant pattern and carries risk to first-degree relatives. Surveillance of SDH mutation carriers should include upper endoscopy every 2–3 years, abdominal imaging, and biochemical screening for paraganglioma (plasma metanephrines). Patients with Carney triad require lifelong multidisciplinary surveillance for pulmonary chondroma and paraganglioma in addition to GIST monitoring. Surveillance CT or MRI every 3–6 months during treatment and every 6 months for 5 years after resection is recommended per NCCN.

Any child or adolescent with unexplained iron-deficiency anemia, recurrent GI bleeding, hematemesis, or a palpable abdominal mass requires urgent evaluation by a pediatric gastroenterologist or surgeon. Young females with unexplained chronic anemia and upper GI bleeding should be investigated for gastric GIST before attributing symptoms to benign peptic disease. If a submucosal gastric mass is identified on imaging or endoscopy in a patient under 30, referral to a specialist center with expertise in pediatric or wild-type GIST is strongly recommended. Patients with concurrent paraganglioma and gastric tumors should be evaluated for Carney triad or Carney-Stratakis syndrome by a multidisciplinary team including genetics, endocrinology, and oncology.